Clinical Trial Details
EORTC-40071
Back to Clinical Trials Database
Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma of the stomach or the esophagogastric junction, metastatic or not amenable to curative surgery according to HER2 and EGFR status: a randomized phase II trial.
| Trial Status | All trial activities ended |
|---|---|
| Dates |
Date of activation: 09-Dec-2010 Date Step1 close: 09-Aug-2013 |
| Data management at EORTC | Yes |
| Design |
Phase 2 Randomized blind |
| Targeted Sample size | EORTC Groups: 192 - All Groups: 192 |
| Treatment | |
| Study Staff | |
| Type of cancer | |
| Participating groups | |
| Protocol summary | http://clinicaltrials.gov/study/NCT01123473 |
| NCT number | NCT01123473 |
| EudraCT | 2009-011580-36 |
